Merck strikes €1.4bn deal with Hengrui Pharmaceuticals for next-gen oncology treatments
In a major advancement in cancer treatment, Merck, a frontrunner in science and technology, has declared a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. This significant partnership focuses on an exclusive license globally (excluding China) to advance, produce, and market Hengrui’s novel and potent PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor, HRS-1167. Furthermore, the […]